at 40K US dollars per patient, 100k patients that is 4 bil US dollars. 40k is a reasonable, relatively low price compared to most new meds for auto immune indications. 100k patients is another conservative figure. 2X revenue is also quite conservative as a buyout number. Not to mention a future partnership for DES which will likely incorporate a very high upfront payment and a substantial future revenue stream in double digits which will add to that buyout number. 80 per share seems very possible in light of the high probability for the success of Voclosporin.
News 
Market Data 
Discover 
